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Abstract: Ulcerative colitis (colitis ulcerosa) is a non-specific inflammatory bowel disease of unknown etiology. The
symptoms which are observed in the course of ulcerative colitis are: an increase in the number of leukocytes and
blood platelets, an increase in the concentration of IL-6 and anemia. Blood platelets are the key element, linking
the processes of hemostasis, inflammation and the repair of damaged tissues. Activation of blood platelets is con-
nected with changes in their shape and the occurrence of the reaction of release. P-selectin appears on the surfaces
of activated blood platelets and the concentration level of soluble P-selectin increases in the blood plasma. The aim
of this study was to define whether the increased number of blood platelets in patients with ulcerative colitis
accompanies changes in their activation and morphology. A total of 16 subjects with ulcerative colitis and 32
healthy subjects were studied. Mean platelet count, morphological parameters of platelets and MPC were mea-
sured using an ADVIA 120 hematology analyzer. Concentrations of sP-selectin and IL-6 in serum were marked by
immunoassay (ELISA). MPC, concentration of sP-selectin and IL-6 were significantly higher in subjects with ul-
cerative colitis compared to those in the healthy group. There was a decrease of MPV in patients with ulcerative
colitis, which is statistically significant. Chronic inflammation in patients with ulcerative colitis causes an increase in
the number of blood platelets, a change in their morphology and activation. Decreased MPV value reflects activa-
tion and the role blood platelets play in the inflammatory process of the mucous membrane of the colon. A high
concentration of sP-selectin, which is a marker of blood platelet activation, demonstrates their part in the inflam-
matory process. The increase in the concentration of sP-selectin correlated positively with the increase in concen-
tration of IL-6. This is why it may be a useful marker of the activity of colitis ulcerosa. (Folia Histochemica et
Cytobiologica 2011; Vol. 49, No. 1, pp. 119–124)
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Introduction
Ulcerative colitis (colitis ulcerosa) is an incurable
chronic disease which features periods of exacerba-
tion and remission. The many causes of ulcerative
colitis include genetic, environmental and bacterial
factors as well as disorders of the intestinal immune
system. The main roles in the pathogenesis of ulcera-
tive colitis are played by immunological disorders,
which are the result of an imbalance between pro-
and anti-inflammatory cytokines. A diffused, non-
specific inflammatory process in the mucous mem-
brane of the colon starts in the rectum and extends
proximately and continuously to the lower part of
the ileum. In the active form of colitis ulcerosa,
a rubicund, granular, swollen, matt bleeding of the
mucous membrane is observed in endoscopy. In
heavy cases of colitis ulcerosa ulceration, pseudopo-
lyps and large amounts of mucus, pus and blood in
the inside of the bowel have been observed. The large
inflammatory infiltration consists of macrophages,
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neutrophils and plasma cells [1, 2]. In the active
forms of non-specific inflammatory bowel disease,
the population of lymphocytes T and B and mac-
rophages located in the mucous membrane is in-
creased. There is also an activation of granulocytes
and local secretion of cytokines (e.g. IL-1, IL-6, IL-8,
TNF-a) and the production of IgG [3, 4]. In labora-
tory studies, the characteristics of inflammation can
be found, such as an increase in the concentration
of C-reactive protein (CRP), quicker erythrocyte
sedimentation rate (ESR), increased number of
blood platelets (PLT), leukocytosis, sideropenic ane-
mia together with hipoalbumin, electrolytic disor-
ders and perinuclear anti-neutrophil cytoplasmic
antibodies (pANCA) [5, 6].
An additional marker of the inflammatory process
may be interleukin-6 (IL-6), which is a pro-inflam-
matory cytokine with multidirectional activity [7]. Pre-
vious studies have shown that there is an increase in
the concentration of IL-6 in ulcerative colitis and its
role is to initiate, potentiate and sustain the inflam-
matory process in the inflamed mucous membrane
of the colon [8–10]. Cytokines and interactions bet-
ween blood cells cause the activation of blood plate-
lets [1, 11].
Blood platelets are the smallest (diameter: 1.5–
–3.5 mm), discoid in shape, non-nucleated cells in the
blood. They are the key element linking the proces-
ses of hemostasis, inflammation and the repair of
damaged tissue. Blood platelets participate in the
complex mechanisms of stopping bleeding where
damage to a blood vessel wall has occurred, and they
participate in the formation of blood clots. Platelets
initiate and support inflammatory processes through:
the secretion of numerous biologically active substan-
ces stored in their granules, e.g. they release: platelet
activation factor (PAF), platelet-derived growth fac-
tor (PDGF), platelets factor 4 (PF4), beta-trombo-
globulin (b-TG), interleukin-1 (IL-1), leukotriens and
prostaglandins [12–16].
The cytotoxic properties of blood platelets are
inter alia cytokine-induced — by cytokines such as
tumor necrosis factor (TNF), IL-6 and gamma-in-
terferon (g-IFN). In some inflammatory diseases,
after the activation of blood platelets there is a re-
lease of alpha granules and fusion of granule mem-
branes with the blood cell membrane. The activa-
tion of blood platelets causes the conformation
changes to GMP-140 molecule (CD 62P, P-selectin,
PADGEM) stored in alpha granules and its integra-
tion into blood platelets cell membranes where it
functions as a CD62P receptor. P-selectin is recog-
nized as a typical marker of blood platelets activa-
tion, as well as the reaction of release of cell gran-
ules [17]. P-selectin occurs also in plasma as soluble
P-selectin (sP-selectin). Both of these P-selectin
forms are a ligand for the Sialyl Levis particle X-CD
15s and sulphoned sequence tyrosine of P-selectin
glycoprotein ligand-1 (PSGL-1) which is constant-
ly present on the surface of phagocytes and neu-
trophils. The interlinking of CD 62P and PSGL-1
activates monocyte, proinflammatory and prothrom-
bose reactions, including the expression of tissue fac-
tor. P-selectin takes part in the migration of white
blood cells during the inflammatory process caus-
ing their adhesion and ‘rolling’ of the white blood
cell on the endothelial cells in blood vessels [1]. An
increased concentration of sP-selectin has been
found in the course of inflammatory and cancerous
processes [16–19].
The aim of our study was to define whether the
increase in the number of blood platelets in patients
with ulcerative colitis is accompanied by changes in
their activation and morphology.
Mean platelet volume (MPV) and large blood
platelets (LPLT) indirectly may be an indication of
the activation of blood platelets. We investigated the
correlation between the inflammatory process and the
activation of blood platelets. As an indication of the
inflammatory process, the concentration of IL-6 was
assayed. In order to define the activation of blood
platelets, the concentration of sP-selectin was evalu-
ated and mean platelet component concentration
(MPC, a potential marker of activation of blood plate-
lets) was assayed. Our studies were approved by the
Local Ethics Commission: Resolution No. R-I-002/
/42/2007.
Material and methods
Subjects
The subjects in this study comprised 16 patients, nine
males and seven females, aged 18–60. The subjects
were hospitalized in III Department of General
Medicine and Gastroenterology of the Regional
General Hospital in Bialystok. All the subjects were
diagnosed with ulcerative colitis. At the moment of
taking blood for analysis, their condition was in an
exacerbation and their clinical status was described
as serious. The activity of the disease was classified
according to Truelove and Witts’s criteria for colitis
ulcerosa into mild, moderate or severe. In the study
group, six subjects were diagnosed with severe coli-
tis ulcerosa (hemoglobin concentration less than 10.5
g/dl; frequency of daily bowel movements six or more
with substantial rectal bleeding), while in the other
ten subjects mild intensification of the disease was
observed, without anemia or fever, and with mini-
mal rectal bleeding.
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The control group comprised 32 healthy subjects,
11 males and 21 females, who came to different clin-
ics of the University Hospital in Bialystok for period-
ic check-ups required by their employers under the
present Labour Code. These patients were not hos-
pital patients.
Materials
All tests in the study group and the control group were
performed simultaneously. Material for analysis includ-
ed venous blood collected directly into BD Vacutainer
vacuum test-tubes onto an anticoagulant K2EDTA (to
determine the PLT and their morphological parame-
ters, as well as MPC) and on clotted blood (to assess
the concentration of sP-selectin and IL-6).
Methods
The amount of blood platelets and their morpholo-
gical parameters (MPV and LPLT), as well as MPC,
were determined using a Bayer Advia 120 hematolo-
gy analyzer. The concentrations of sP-selectin and IL-
6 were determined by the immunoassay method us-
ing R&D Systems ELISA Kit Human sP-selectin and
ELISA Quantikine HS Human IL-6.
ELISA (enzyme-linked immunosorbent assay)
employs the quantitative sandwich immunoassay tech-
nique, in which monoclonal antibodies specific for sP-
-selectin are pre-coated onto a microplate and bind
sP-selectin present in the blood samples. During in-
cubation with sP-selectin conjugate (second antibody
to sP-selectin conjugated with horseradish peroxi-
dase), the immunology complex is created: a mono-
clonal antibody specific to sP-selectin- sP-selectin con-
jugate. After adding substrate and terminating the
reaction with Stop Solution, the intensity of the color
reaction is determined using a spectrophotometer.
The color intensity is proportional to the sP-selectin
concentration in the plasma.
The quantitative determination of human IL-6 con-
centration in serum was carried out using R&D Sys-
tems ELISA Quantikine HS Human IL-6. This test is
based on the quantitative sandwich immunoassay tech-
nique. Monoclonal antibodies specific for IL-6 are pre-
coated onto a microplate and bind IL-6 present in the
blood samples. After washing any unbound antibodies,
a conjugate is added. During the incubation, a ‘sand-
wich structure’ is created where the antigen forms
a layer between two antibodies. Adding a substrate to
the enzyme (alkaline phosphate) joined to the anti-
body produces a reaction that manifests itself as a co-
lor change. Following a period of incubation, an ampli-
fier solution is added to the wells. This enables the color
to develop in proportion to the amount of IL-6 bound
in the initial step. Color development is then stopped
and the intensity of the color measured.
Statistical analysis
The results of the study were statistically analyzed
using Statistica 8.0 PL. Arithmetic mean and stan-
dard deviations were calculated for the subjects with
ulcerative colitis and the control group. Statistical
analysis between the study group (B) and the control
group (C) were performed using the parametric Stu-
dent t-test for two independent determinants with
normal distribution. Results were considered statisti-
cally significant at p < 0.05. To determine the corre-
lation between the inflammatory process and the ac-
tivation of blood platelets, a correlation test was per-
formed using determinants for normal distribution
applying Pearson’s coefficient.
Results
The amount of blood platelets (PLT) in patients with
ulcerative colitis (B) was 300.56 ± 110.96 G/L and
was significantly higher (p < 0.001) compared to the
mean platelet count in the control group (C) (248 ±
± 44.74 G/L) (Table 1).
Mean platelet volume (MPV) was significantly
lower (p < 0.05) in the study group B (8.03 ± 0.83 fl)
than the mean value in the control group C (8.68 ±
± 0.64 fl) (Table 1).
The analysis of the amount of large blood plate-
lets (LPLT) in both groups proved to be statistically
insignificant (0.3 < p < 0.4) being: 4.75 ± 2.21 G/L
in group B and 5.34 ± 1.81 G/L in group C (Table 1).
Comparison of the results of the value of MPC in
groups B and C showed that average MPC in patients
with ulcerative colitis was 26.45 ± 1.45 g/dl; this was
slightly higher than in the control group (25.70 ± 1.37
g/dl). The difference between groups B and C was not
statistically significant (0.7 < p < 0.8) (Table 1).
It was demonstrated that the concentration of sP-
-selectin was significantly increased (p < 0.01) in pa-
tients with ulcerative colitis compared to the healthy
subjects. Mean concentrations of sP-selectin in group
B was 22.33 ± 20.82 ng/ml, which is almost treble the
mean concentration of sP-selectin in group C (7.26 ±
± 6.59 ng/ml) (Table 2).
In patients with ulcerative colitis (B) the mean
concentration of IL-6 (6.04 ± 4.37 pg/ml) was twice
as high as the mean concentration of IL-6 in the con-
trol group (C), which was 2.45 ± 1.44 pg/ml. This dif-
ference is statistically significant (p < 0.01) (Table 2).
The correlation between the concentration of IL-6
and the concentration of sP-selectin was positive at
r = 0.35, but was not statistically significant (p < 0.5).
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Discussion
Ulcerative colitis (colitis ulcerosa) is a form of chro-
nic non-specific inflammatory bowel disease. Among
many factors which contribute to the etiopathogene-
sis of colitis ulcerosa are genetic conditioning, food
allergies and bacterial, viral and environmental fac-
tors. They affect the mucous membrane of the colon
and lead to disorders of the intestinal immune sys-
tem. IL-6 may be the sensitive but non-specific mark-
er of the inflammatory process in a human body; its
concentration in blood plasma can increase up to
100-fold during inflammation. A study by Wędry-
chowicz et al. showed that the concentration of IL-6
in blood plasma is increased in patients with active
ulcerative colitis, whereas it is decreased in patients
in the period of remission of ulcerative colitis [20].
Raddatz et al. studied IL-6-mRNA expression in bio-
psy samples of inflamed mucosa and in the periphe-
ral blood mononuclear cells (PBMNC) from patients
with non-specific inflammatory bowel diseases [21].
It was demonstrated that increased IL-6 expression
occurred in inflamed mucous membrane of the colon
correlating with the extent of the disease process and
CRP levels in subjects with pancolitis ulcerosa.
Our study demonstrated that the concentration of
IL-6 in the ulcerative colitis group of subjects was al-
most three times higher than the concentration of IL-6
in the healthy group. This shows that IL-6 may be a use-
ful marker of inflammatory activity of colitis ulcerosa
in inflamed mucosa in subjects suffering from colitis
ulcerosa. However, the determination of concentra-
tion of IL-6 in mucosal biopsies may help to differen-
tiate Crohn’s disease from ulcerative colitis.
IL-6 induces many biological effects, such as the
stimulation of blood platelets activation. The acti-
vation of blood platelets causes the appearance of
P-selectin on their surface which, as a receptor pro-
tein, contributes to the pathogenesis of inflammation
and thrombosis [1]. A part of P-selectin peels from
the surface of blood platelets and occurs in plasma in
a soluble form. The present study shows that the con-
centration of sP-selectin in subjects with ulcerative
colitis was higher than in the control group, which
was statistically significant (p < 0.01). Such increases
in sP-selectin concentrations prove the activation of
blood platelets and their part in the inflammatory
process.
An increase in the concentration of IL-6 is a mark-
er of inflammatory process in the mucous mem-
brane of the colon. An increase in the concentration
of sP-selectin indicates the activation of blood plate-
lets and their part in the inflammatory process. In the
present study, positive correlations between concen-
trations of IL-6 and sP-selectin were found in sub-
jects with ulcerative colitis, but this was not statisti-
cally significant.
An increase in the number of blood platelets has
been observed in the course of chronic inflammatory
bowel disease [5, 6]. In the present study, morpho-
logical parameters of platelets were also analyzed
(MPV, LPLT), which may change in relation to their
functional state and measurement of the parameters
may indirectly indicate the degree of blood platelets
Table 2. Concentrations of sP-selectin and IL-6 in both groups (B and C)
Subjects (B) Control group (C) Statistical significance
n = 16 n = 23 p
X ± SD X ± SD
sP-selectin [ng/ml] 22.33 ± 20.82 7.26 ± 6.59 p < 0.01*
IL-6 [pg/ml] 6.04 ± 4.37 2.45 ± 1.44 p < 0.01*
n — number of cases; X — arithmetic mean; SD — standard deviation; Student’s t-test; *p < 0.05 statistically significant differences
Table 1. Mean platelet count and their morphological parameters in groups B and C
Subjects (B) Control group (C) Statistical significance
n = 16 n = 32 p
X ± SD X ± SD
Mean platelet count [G/L] 300.56 ± 110.96 248 ± 44.74 p < 0.01*
Mean platelet volume [fl] 8.03 ± 0.83 8.68 ± 0.64 p < 0.05*
Large blood platelets [G/L] 4.75 ± 2.21 5.34 ± 1.81 0.3 < p < 0.4
Mean platelet component concentration [g/dl] 26.45 ± 1.45 25.70 ± 1.37 0.7 < p < 0.8
n — number of cases; X — arithmetic mean; SD — standard deviation; Student’s t-test; *p < 0.05 statistically significant differences
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activation [22, 23]. Our study demonstrated that the
PLT in subjects with ulcerative colitis (B) was signifi-
cantly higher compared to the PLT in the control
group (C). Previous studies have shown that the blood
platelet count was increased in patients with active
colitis ulcerosa compared to inactive colitis ulcerosa
or healthy subjects. Here there was a difference bet-
ween study groups which was statistically significant
[24]. In the present study, the number of metaboli-
cally active immature large blood platelets was deter-
mined. It was demonstrated that their number was
slightly lower in subjects with ulcerative colitis com-
pared to the control group, and that this difference
was not statistically significant.
These results suggest the hypothesis that active
large blood platelets are used up in the inflammatory
process and that smaller platelets influence a decrease
of MPV. Other studies have also shown that the num-
ber of reticulated platelets was reduced in active ul-
cerative colitis patients compared to inactive ulce-
rative colitis patients and healthy subjects [24].
It needs to be remembered that the decrease in
MPV in subjects with active ulcerative colitis can be
associated with the increase of blood platelets activa-
tion in these patients. In the present study, MPV was
significantly lower in the ulcerative colitis group (B)
compared to the control group (C), something which
agreed with the results of other studies [6, 25]. The
aim of the study by Yüksel et al. [6] was to determine
whether mean platelet volume would be a useful
marker of ulcerative colitis, and to analyze its overall
accuracy in evaluating disease activity in comparison
with other inflammatory markers (leucocytosis, ESR,
concentration of CRP). The study showed that MPV
was reduced in colitis ulcerosa compared to the con-
trol group, and that the reduction was statistically sig-
nificant. MPV values in active colitis ulcerosa (8.06 ±
± 1.19 fl) and inactive colitis ulcerosa (8.45 ± 0.87 fl)
were compared. The differences were shown to be
statistically significant. In ulcerative colitis, MPV did
not correlate with other markers: leucocytosis, ESR
and CRP. On the basis of the results, it appears that
decreased MPV may be an indicator for increased
disease activity in patients with colitis ulcerosa. Paral-
lel dependencies between activity of ulcerative colitis
and mean platelet volume were observed in the study
by Kayahan et al. [24].
In 2001, Kapsoritakis et al. studied two groups
of patients with inflammatory bowel disease, compri-
sing 93 subjects with colitis ulcerosa (CU), 66 with
Crohn’s disease (CD) and 38 healthy subjects [25].
The activity of disease was defined using the Clinical
Colitis Activity Index for patients with colitis ulcerosa
and the Crohn’s Disease Activity Index for patients
with Crohn’s disease. In all groups, blood platelet
count and their morphological parameters were mea-
sured.
It was shown that the complete blood platelet
count was significantly increased in patients with ac-
tive CU and CD compared to patients with inactive
CU and CD or healthy subjects. In the case of MPV,
parallel dependencies were demonstrated. MPV was
significantly reduced in active inflammatory bowel
diseases and correlated negatively with leucocytosis,
ESR, concentration of CRP, markers of activation of
blood platelets, such as plasma b-TG and PF4. The
increase in the concentration of plasma b-TG and PF4
indicate platelets activation and the release of active
biological substances, which are stored in the plate-
let’s granules. They initiate and support the inflam-
matory process in the colon. The increase in the com-
plete blood platelet count and the reduction in MPV
reflected this process.
In the study, the usefulness of potential MPC
marker of blood platelets activation (degree of their
degranulation) was also analyzed; the value of MPC
depends on the content of cell granules of blood plate-
lets. Activation of blood platelets and the release of
active biological substances outside the blood plate-
lets cause changes in the cytoskeleton of activated
platelets and the reduced density of the platelet’s
components. The indication marker of this process
is a decrease in MPC value, although this was not de-
monstrated in the study.
The examples given above indicate that blood
platelets play an important part in the inflammatory
process in patients with colitis ulcerosa. MPV — simi-
larly to the increase of the number of leukocytes, the
concentration of CRP and the quicker ESR — may
be an indication of exacerbation of the inflammatory
process in the mucous membrane of the colon. A high
concentration of IL-6 reflects the inflammatory pro-
cess, while the increase in sP-selectin concentration
reflects the participation of blood platelets in these
processes.
Conclusions
Chronic inflammatory process in patients with ulcer-
ative colitis causes an increase in the number of blood
platelets and changes in their activation and morpho-
logical parameters. The lower value of LPLT in sub-
jects may indicate that large metabolically active blood
platelets take part in the inflammatory process in the
colon. A decrease in MPV reflects activation and par-
ticipation of blood platelets in the inflammatory pro-
cess of the colon mucosa, and because of this, MPV
may be a useful marker of active ulcerative colitis.
A high concentration of sP-selectin, which is a mark-
er of activation of blood platelets, reflects its partici-
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pation in the inflammatory process. The increase in
the concentration of sP-selectin correlated positively
with the increase in the concentration of IL-6 and
this is why sP-selectin may be a useful marker of ac-
tive ulcerative colitis.
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